Fennec Pharma trims Board as director retires

Fennec Pharmaceuticals Inc. reported a planned change to its Board of Directors.

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Fennec Pharmaceuticals Inc. reported a planned change to its Board of Directors. On April 27, 2026, director Rostislav Raykov notified the company that he plans to retire from the Board and will not stand for re-election at the 2026 annual meeting of shareholders.

His current term will end immediately after the annual meeting, and his departure is stated to be not due to any disagreement with the company’s operations, policies, or practices. Before the meeting, the Board decided to reduce its size from six to five directors, effective immediately following the annual meeting, and the company expects no Board vacancies after the change.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Notification date: April 27, 2026 Board size before change: 6 directors Board size after change: 5 directors

3 metrics

Notification date April 27, 2026 Date Mr. Raykov informed the company of his retirement plans

Board size before change 6 directors Board composition prior to the 2026 annual meeting decision

Board size after change 5 directors Effective immediately following the 2026 annual meeting

Key Terms

Board of Directors, annual meeting of shareholders, Emerging growth company, principal officers

4 terms

Board of Directors financial

"retire from the Company's Board of Directors (the "Board")"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

annual meeting of shareholders financial

"will not stand for re-election at the Company's 2026 annual meeting of shareholders"

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

principal officers regulatory

"Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What Board change did Fennec Pharmaceuticals (FENC) disclose in this 8-K?

Fennec Pharmaceuticals disclosed that director Rostislav Raykov plans to retire from its Board and will not stand for re-election at the 2026 annual meeting. His term will end immediately after the meeting, and the Board will then be reduced from six to five directors.

Why is Fennec Pharmaceuticals (FENC) director Rostislav Raykov leaving the Board?

The company states that Rostislav Raykov is retiring from the Board and will not seek re-election at the 2026 annual meeting. It specifically notes his departure is not due to any disagreement about the company’s operations, policies, or practices, indicating a routine transition.

When will Rostislav Raykov’s term on Fennec Pharmaceuticals’ (FENC) Board end?

Rostislav Raykov’s current term will expire immediately following Fennec Pharmaceuticals’ 2026 annual meeting of shareholders. Until that meeting, he remains a director, after which his planned retirement from the Board will take effect as previously communicated to the company.

How will the size of Fennec Pharmaceuticals’ (FENC) Board change after the 2026 annual meeting?

Prior to the annual meeting, the Board decided to reduce its size from six directors to five, effective immediately following the meeting. After Mr. Raykov’s departure and this reduction, the company expects to have a five-member Board with no vacant director seats.

Does Fennec Pharmaceuticals (FENC) expect any Board vacancies following Raykov’s retirement?

The company states that following the 2026 annual meeting and Rostislav Raykov’s departure, it expects there will be no vacancies on the Board. This reflects the Board decision to reduce its size from six directors to five at that time.

What form did Fennec Pharmaceuticals (FENC) use to report this Board change?

Fennec Pharmaceuticals used a Form 8-K to report the planned retirement of director Rostislav Raykov and the related Board size reduction. The disclosure appears under Item 5.02, which covers departures and appointments of directors and principal officers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 04/28/2026 - 04:46 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 27, 2026

FENNEC PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

001-32295

(Commission File Number)

British Columbia, Canada

20-0442384

(State or other jurisdiction of

incorporation)

(I.R.S. Employer Identification No.)

PO Box 13628, 68 TW Alexander Drive,

Research Triangle Park, NC

27709

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (919) 636-4530

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


	☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


	☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


	☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


	☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12 of the Act:


Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common shares, no par value	FENC	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02.

Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

On April 27, 2026, Rostislav Raykov notified Fennec Pharmaceuticals Inc. (the "Company") of his desire to retire from the Company's Board of Directors (the "Board") and that he will not stand for re-election at the Company's 2026 annual meeting of shareholders (the "Annual Meeting"). Mr. Raykov’s current term will expire immediately following the Annual Meeting.

Mr. Raykov's departure is not due to any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

Prior to the Annual Meeting, the Board determined to reduce the size of the Board from six directors to five directors effective immediately following the Annual Meeting. Following the Annual Meeting and Mr. Raykov's departure, the Company expects that there will be no vacancies on the Board.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


		FENNEC PHARMACEUTICALS INC.


Date April 28, 2026	By:	/s/ Robert Andrade
		Robert Andrade Chief Financial Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents